Overview

Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate

Status:
Unknown status
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the response of erectile dysfunction in hypogonadotrophic males with Testosterone undecanoate i.m. as per IIEF and the question of the GAQ (Global Evaluation Questionnaire) after 42 weeks of treatment. Secondary Study Objectives - To monitor adverse events and changes in hemoglobin and serum chemistry with: PSA, lipid profile, renal-hepatic profile and glycemia, and control by means of a rectal digital examination. - To Determinate physiologic reconstitution in patients under treatment by means of total and free testosterone dosage.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Santa Fe
Collaborator:
Bayer
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate